NCT05098275View on ClinicalTrials.gov

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

February 6, 2022

Study Completion Date

February 6, 2022

Conditions
Healthy
Interventions
DRUG

DA-5210 10/500mg

single dose administration (one tablet once a day)

DRUG

DA-5210-R 10/500mg

single dose administration (one tablet once a day)

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT05098275 - Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State | Biotech Hunter | Biotech Hunter